TERM ID="NYU_TERM_1" STRING="BSC" FREQUENCY=1 START=1903 END=1906 LEMMA="BEST SUPPORTIVE CARE" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_2" STRING="BSC arm" FREQUENCY=1 START=2242 END=2249 LEMMA="BSC ARM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_3" STRING="CLL" FREQUENCY=2 START=367 END=370 LEMMA="CHRONIC LYMPHOCYTIC LEUKAEMIA" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_4" STRING="CLL" FREQUENCY=2 START=1405 END=1408 LEMMA="CHRONIC LYMPHOCYTIC LEUKAEMIA" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_5" STRING="Clinical Excellence" FREQUENCY=1 START=460 END=479 LEMMA="CLINICAL EXCELLENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_6" STRING="Complete resolution" FREQUENCY=1 START=952 END=971 LEMMA="COMPLETE RESOLUTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_7" STRING="Complete resolution of constitutional symptoms" FREQUENCY=1 START=952 END=998 LEMMA="CONSTITUTIONAL SYMPTOM COMPLETE RESOLUTION" LEMMA_FREQUENCY=1 HEAD_TERM="Complete resolution" HEAD_LEMMA="COMPLETE RESOLUTION"
TERM ID="NYU_TERM_8" STRING="Cox" FREQUENCY=1 START=2578 END=2581 LEMMA="COX" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_9" STRING="Cox proportional hazards" FREQUENCY=1 START=2578 END=2602 LEMMA="PROPORTIONAL HAZARD COX" LEMMA_FREQUENCY=1 HEAD_TERM="proportional hazards" HEAD_LEMMA="PROPORTIONAL HAZARD"
TERM ID="NYU_TERM_10" STRING="DR" FREQUENCY=1 START=1484 END=1486 LEMMA="DOUBLE REFRACTORY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="DR CLL" FREQUENCY=1 START=1832 END=1838 LEMMA="DR CLL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_12" STRING="GSK" FREQUENCY=1 START=159 END=162 LEMMA="GSK" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_13" STRING="Hx-CD20-406 study" FREQUENCY=3 START=850 END=867 LEMMA="HX-CD20-406 STUDY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_14" STRING="Hx-CD20-406 study" FREQUENCY=3 START=2281 END=2298 LEMMA="HX-CD20-406 STUDY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_15" STRING="Hx-CD20-406 study" FREQUENCY=3 START=2430 END=2447 LEMMA="HX-CD20-406 STUDY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_16" STRING="MS" FREQUENCY=2 START=415 END=417 LEMMA="MULTIPLE SCLEROSIS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_17" STRING="MS" FREQUENCY=2 START=1305 END=1307 LEMMA="MULTIPLE SCLEROSIS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_18" STRING="Median progression-free survival" FREQUENCY=1 START=1060 END=1092 LEMMA="MEDIAN PROGRESSION-FREE SURVIVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_19" STRING="OS" FREQUENCY=2 START=1121 END=1123 LEMMA="OVERALL SURVIVAL" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_20" STRING="OS" FREQUENCY=2 START=2622 END=2624 LEMMA="OVERALL SURVIVAL" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_21" STRING="Ofatumumab" FREQUENCY=1 START=0 END=10 LEMMA="OFATUMUMAB" LEMMA_FREQUENCY=7
TERM ID="NYU_TERM_22" STRING="PFS" FREQUENCY=2 START=1094 END=1097 LEMMA="PROGRESSION FREE SURVIVAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_23" STRING="PFS" FREQUENCY=2 START=2614 END=2617 LEMMA="PROGRESSION FREE SURVIVAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_24" STRING="alemtuzumab" FREQUENCY=2 START=112 END=123 LEMMA="ALEMTUZUMAB" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_25" STRING="alemtuzumab" FREQUENCY=2 START=1452 END=1463 LEMMA="ALEMTUZUMAB" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_26" STRING="area-under-the-curve" FREQUENCY=1 START=1700 END=1720 LEMMA="AREA-UNDER-THE-CURVE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_27" STRING="base-case" FREQUENCY=1 START=2907 END=2916 LEMMA="BASE-CASE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_28" STRING="base-case incremental cost-effectiveness ratio" FREQUENCY=1 START=2907 END=2953 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO BASE-CASE" LEMMA_FREQUENCY=1 HEAD_TERM="incremental cost-effectiveness ratio" HEAD_LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO"
TERM ID="NYU_TERM_29" STRING="best supportive care" FREQUENCY=1 START=1881 END=1901 LEMMA="BEST SUPPORTIVE CARE" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_30" STRING="biased cost-effectiveness" FREQUENCY=1 START=2720 END=2745 LEMMA="BIASED COST-EFFECTIVENESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_31" STRING="chronic lymphocytic leukaemia" FREQUENCY=3 START=336 END=365 LEMMA="CHRONIC LYMPHOCYTIC LEUKAEMIA" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_32" STRING="chronic lymphocytic leukaemia" FREQUENCY=3 START=32 END=61 LEMMA="CHRONIC LYMPHOCYTIC LEUKAEMIA" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_33" STRING="chronic lymphocytic leukaemia" FREQUENCY=3 START=336 END=365 LEMMA="CHRONIC LYMPHOCYTIC LEUKAEMIA" LEMMA_FREQUENCY=5
TERM ID="NYU_TERM_34" STRING="clinical effectiveness" FREQUENCY=1 START=244 END=266 LEMMA="CLINICAL EFFECTIVENESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_35" STRING="clinical evidence" FREQUENCY=1 START=553 END=570 LEMMA="CLINICAL EVIDENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="confidence interval" FREQUENCY=1 START=908 END=927 LEMMA="CONFIDENCE INTERVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_37" STRING="constitutional symptoms" FREQUENCY=1 START=975 END=998 LEMMA="CONSTITUTIONAL SYMPTOM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_38" STRING="cost-effectiveness" FREQUENCY=1 START=271 END=289 LEMMA="COST-EFFECTIVENESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_39" STRING="cost-effectiveness of ofatumumab" FREQUENCY=1 START=271 END=303 LEMMA="OFATUMUMAB COST-EFFECTIVENESS" LEMMA_FREQUENCY=1 HEAD_TERM="cost-effectiveness" HEAD_LEMMA="COST-EFFECTIVENESS"
TERM ID="NYU_TERM_40" STRING="critical appraisal" FREQUENCY=1 START=1510 END=1528 LEMMA="CRITICAL APPRAISAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_41" STRING="economic evaluation" FREQUENCY=1 START=2204 END=2223 LEMMA="ECONOMIC EVALUATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_42" STRING="economic outcomes" FREQUENCY=1 START=1796 END=1813 LEMMA="ECONOMIC OUTCOME" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_43" STRING="evidence review group" FREQUENCY=1 START=200 END=221 LEMMA="EVIDENCE REVIEW GROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_44" STRING="final appraisal determination" FREQUENCY=1 START=3027 END=3056 LEMMA="FINAL APPRAISAL DETERMINATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_45" STRING="fludarabine" FREQUENCY=1 START=1436 END=1447 LEMMA="FLUDARABINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_46" STRING="incremental cost-effectiveness ratio" FREQUENCY=1 START=2917 END=2953 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_47" STRING="infusion reactions" FREQUENCY=1 START=1224 END=1242 LEMMA="INFUSION REACTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_48" STRING="life-year" FREQUENCY=1 START=3012 END=3021 LEMMA="LIFE-YEAR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_49" STRING="manufacturer" FREQUENCY=2 START=387 END=400 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_50" STRING="manufacturer" FREQUENCY=2 START=1594 END=1607 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_51" STRING="non-comparative" FREQUENCY=1 START=675 END=690 LEMMA="NON-COMPARATIVE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_52" STRING="non-randomised" FREQUENCY=1 START=593 END=607 LEMMA="NON-RANDOMISED" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_53" STRING="non-randomised study" FREQUENCY=1 START=1674 END=1694 LEMMA="NON-RANDOMISED STUDY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_54" STRING="non-responders" FREQUENCY=1 START=2346 END=2360 LEMMA="NON-RESPONDER" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_55" STRING="ofatumumab" FREQUENCY=6 START=293 END=303 LEMMA="OFATUMUMAB" LEMMA_FREQUENCY=7
TERM ID="NYU_TERM_56" STRING="ofatumumab" FREQUENCY=6 START=738 END=748 LEMMA="OFATUMUMAB" LEMMA_FREQUENCY=7
TERM ID="NYU_TERM_57" STRING="ofatumumab" FREQUENCY=6 START=1323 END=1333 LEMMA="OFATUMUMAB" LEMMA_FREQUENCY=7
TERM ID="NYU_TERM_58" STRING="ofatumumab" FREQUENCY=6 START=1867 END=1877 LEMMA="OFATUMUMAB" LEMMA_FREQUENCY=7
TERM ID="NYU_TERM_59" STRING="ofatumumab" FREQUENCY=6 START=2759 END=2769 LEMMA="OFATUMUMAB" LEMMA_FREQUENCY=7
TERM ID="NYU_TERM_60" STRING="ofatumumab" FREQUENCY=6 START=2958 END=2968 LEMMA="OFATUMUMAB" LEMMA_FREQUENCY=7
TERM ID="NYU_TERM_61" STRING="ofatumumab arm" FREQUENCY=1 START=2372 END=2386 LEMMA="OFATUMUMAB ARM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_62" STRING="overall survival" FREQUENCY=1 START=1103 END=1119 LEMMA="OVERALL SURVIVAL" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_63" STRING="partitioned-survival" FREQUENCY=1 START=1726 END=1746 LEMMA="PARTITIONED-SURVIVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_64" STRING="performance status" FREQUENCY=1 START=1012 END=1030 LEMMA="PERFORMANCE STATUS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_65" STRING="pre-progression" FREQUENCY=1 START=1955 END=1970 LEMMA="PRE-PROGRESSION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_66" STRING="progression-free survival" FREQUENCY=1 START=1067 END=1092 LEMMA="PROGRESSION-FREE SURVIVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_67" STRING="progressive disease" FREQUENCY=1 START=2668 END=2687 LEMMA="PROGRESSIVE DISEASE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_68" STRING="proportional hazards" FREQUENCY=1 START=2582 END=2602 LEMMA="PROPORTIONAL HAZARD" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_69" STRING="provided evidence" FREQUENCY=1 START=695 END=712 LEMMA="PROVIDED EVIDENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_70" STRING="response rate" FREQUENCY=1 START=881 END=894 LEMMA="RESPONSE RATE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_71" STRING="single-arm" FREQUENCY=1 START=1662 END=1672 LEMMA="SINGLE-ARM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_72" STRING="single-arm study" FREQUENCY=1 START=609 END=625 LEMMA="SINGLE-ARM STUDY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_73" STRING="submitted evidence" FREQUENCY=1 START=2875 END=2893 LEMMA="SUBMITTED EVIDENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_74" STRING="supportive care" FREQUENCY=1 START=1886 END=1901 LEMMA="SUPPORTIVE CARE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_75" STRING="technology appraisal process" FREQUENCY=1 START=509 END=537 LEMMA="TECHNOLOGY APPRAISAL PROCESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_76" STRING="three-state structure" FREQUENCY=1 START=1925 END=1946 LEMMA="THREE-STATE STRUCTURE" LEMMA_FREQUENCY=1
URL ID="NYU_TERM_77" STRING="www.nice.org.uk/nicemedia/live/12264/50758/50758.pdf" FREQUENCY=1 START=3095 END=3147 LEMMA="WWW.NICE.ORG.UK/NICEMEDIA/LIVE/12264/50758/50758.PDF" LEMMA_FREQUENCY=1 HEAD_TERM="WWW.NICE.ORG.UK/NICEMEDIA/LIVE/12264/50758/50758.PDF" HEAD_LEMMA="WWW.NICE.ORG.UK/NICEMEDIA/LIVE/12264/50758/50758.PDF"
